The success of these findings led to clinical investigations, such as the CAR2BRAIN study (NCT03383978), which combines NK92/5.28.z cells with intravenous Ezabenlimab in patients with recurrent HER2-positive glioblastoma. Here, ERBB2 is linked to glioblastoma.